Is Red Light Therapy Safe for Breast Cancer Patients?

Red light therapy, more formally called photobiomodulation (PBM), has not been shown to accelerate tumor growth in the clinical studies conducted so far in breast cancer patients, and a systematic review of the safety literature found no tumor-related safety issues when PBM was used to manage treatment side effects. That said, the evidence base is still limited, the lab data are genuinely mixed, and no major oncology guideline has given a blanket endorsement for using PBM on or near breast tumors. The picture is more nuanced than either “perfectly safe” or “stay away,” and it depends heavily on what the light is being used for and where it is being applied.

How Red Light Interacts With Your Cells

Red and near-infrared light, typically in the 600 to 1,000 nanometer range, penetrates the skin and is absorbed primarily by a protein inside the mitochondria called cytochrome c oxidase. The leading theory is that the light knocks loose a molecule of nitric oxide that had been sitting on that protein and slowing down energy production. Once the nitric oxide is released, the mitochondria resume making energy more efficiently, and the cell ramps up a cascade of repair and signaling activity.¹ This is why PBM can speed wound healing and reduce inflammation in healthy tissue. But when cancer cells are in the picture, the question becomes whether the same metabolic boost could also help tumor cells grow. That is the core tension running through all the research on this topic.

What Lab and Animal Studies Show

The preclinical evidence is a patchwork. Some studies point toward safety or even anti-cancer effects, and others raise caution flags. A 2020 study tested four wavelengths of red LED light on two common breast cancer cell lines and found that 660 nm light reduced the viability of both cell types by about 40 percent within 24 hours, while the other wavelengths had no meaningful effect.² A separate study using low-power red and blue light on the same cell lines found that neither viability nor migration changed, but that the light did reduce the cells’ ability to invade surrounding tissue.³

On the other side, a study using infrared laser on triple-negative breast cancer cells found that at a certain dose the light actually increased cell proliferation.⁴ This is the kind of result that makes oncologists uneasy. The specifics matter enormously: the wavelength, the energy density, and the cell type all influence whether the light nudges cancer cells toward growth, toward death, or does nothing at all.

Animal studies have been somewhat more reassuring. In one experiment, mice carrying transplanted tumors received full-body 670 nm red LED light twice daily for 37 days. Measurements across 330 tumors showed no measurable effect on tumor growth compared to untreated controls.⁵ A second mouse study found that a single red LED session did not increase tumor volume. In fact, at one particular energy dose, the irradiated mice had fewer metastatic nodules in their lungs and survived longer than the control animals.⁶ These are encouraging findings, but mouse models do not always translate cleanly to human cancer biology, and researchers have not run these experiments at every wavelength and dose combination that a patient might encounter.

The Angiogenesis Concern

One of the more specific worries about red light and cancer involves blood vessel formation. Tumors need new blood vessels to feed their growth, and some lab work has shown that red and near-infrared light can promote the production of vascular endothelial growth factor (VEGF) and stimulate the proliferation of endothelial cells, especially under low-oxygen conditions.⁷ In theory, this could give a tumor exactly what it needs to expand its blood supply. However, a study specifically measuring VEGF and the related growth factor TGF-β in endothelial cells exposed to LED light found that neither was markedly changed.⁸ The discrepancy probably comes down to differences in cell type, oxygen levels, and light parameters. But the fact that pro-angiogenic effects have been observed at all under certain conditions is a legitimate reason for caution, especially if light is applied directly over or near a known tumor.

Managing Radiodermatitis During Radiation Therapy

The strongest clinical evidence for PBM in breast cancer patients comes from its use in preventing and treating radiation-induced skin damage. Radiation therapy for breast cancer frequently causes painful skin reactions ranging from redness and itching to blistering and raw, open patches. Several clinical trials have tested whether applying red or near-infrared LED light to the irradiated skin throughout treatment can reduce the severity of these reactions.

A randomized, placebo-controlled trial known as TRANSDERMIS found that only about 7 percent of patients in the laser group developed moderate-to-severe skin reactions by the end of radiation, compared with 30 percent in the placebo group.⁹ Two systematic reviews have confirmed the general trend: LED therapy appears to reduce the severity of radiodermatitis and to decrease the number of treatment interruptions caused by skin breakdown.¹⁰ One review noted that while acute radiodermatitis responded well to LED therapy, chronic cases did not show the same improvement.¹¹ Critically, none of these studies reported any signs that the light therapy interfered with the cancer treatment itself or promoted tumor growth.

Lymphedema After Breast Cancer Surgery

Swelling of the arm on the side where lymph nodes were removed is one of the most persistent and distressing complications of breast cancer treatment. PBM has been studied as a potential add-on therapy for this condition, but the results have been underwhelming so far. A meta-analysis of nine randomized controlled trials involving over 300 patients found no significant reduction in arm circumference, arm volume, grip strength, or pain when PBM was compared to control treatments.¹² An overview of systematic reviews on the topic reached a similar conclusion, noting that the evidence quality was too poor to draw firm conclusions either way.¹³

That does not mean PBM is useless for lymphedema patients, though. One pilot randomized trial found that even though the laser did not shrink arm volume, it did reduce the number of symptoms patients reported, improved their limb mobility, and significantly eased emotional distress, with feelings of sadness dropping from 73 percent to 11 percent in the laser group over 12 months.¹⁴ The swelling itself did not budge, but the experience of living with it apparently improved. Whether that is worth the time and expense is a personal judgment call, but the safety profile in these trials was consistently clean.

Chemotherapy-Induced Nerve Damage

Tingling, numbness, and pain in the hands and feet are common side effects of several chemotherapy drugs used in breast cancer. Two randomized trials have explored whether PBM can help with this problem, and the results hint at a benefit without being definitive. In the NEUROLASER pilot trial, patients receiving PBM alongside chemotherapy did not develop worsening sensory neuropathy symptoms over time the way the control group did. The PBM group also showed better physical endurance at follow-up and a trend toward less pain.¹⁵ A second phase II trial found that patients in both the laser and control groups improved, but improvement lasted longer in the laser group. At 12 weeks, the laser group’s symptoms remained below baseline while the control group was drifting back toward where they started.¹⁶ Both trials reported only low-grade side effects, and neither found any safety concerns related to tumor progression.

Cognitive Effects and Chemobrain

Some researchers have started pointing PBM at the brain itself to see if it can address the cognitive fog many breast cancer patients report during and after treatment, often called chemobrain. A pilot study applying transcranial PBM to breast cancer survivors found a substantial improvement in self-reported cognitive function, with average scores on a validated cognitive questionnaire jumping from about 63 to 101 after treatment.¹⁷ A separate study looked at bright-light therapy (a related but distinct intervention) given to women with breast cancer before they started systemic treatment and found that the bright-light group reported fewer subjective cognitive complaints, though objective test performance was not significantly different between groups.¹⁸ These are early-stage studies with small sample sizes and no long-term follow-up, so they should be taken as intriguing signals rather than proof. But they expand the map of what red light therapy might eventually be used for in cancer care.

The Systematic Review on Tumor Safety

The most directly relevant piece of evidence for the title question is a 2019 systematic review that specifically set out to evaluate whether PBM used for managing cancer treatment side effects caused any tumor safety problems. After reviewing the available literature, the authors concluded that PBM used in this context did not lead to tumor safety issues.¹⁹ That is a meaningful finding, but it comes with caveats. The review noted that much of the existing literature focuses on oral mucositis in head and neck cancer patients, not breast cancer specifically. And “no evidence of harm” is not the same as “proven safe,” especially when the total number of patients studied remains relatively small and follow-up periods are short.

PBM Versus Photodynamic Therapy

A source of confusion worth clearing up: photobiomodulation and photodynamic therapy (PDT) both use light, but they are fundamentally different treatments. PBM uses low-level red or near-infrared light alone, without any drugs, to stimulate cell metabolism. PDT involves injecting or applying a photosensitizing chemical that concentrates in tumor tissue, then hitting the area with light to activate the chemical and destroy the tumor cells. PDT is an active cancer-killing strategy. PBM is not.

Some of the most dramatic research involving red light and breast cancer falls into the PDT category. For example, studies in mouse models of breast cancer have shown that PDT, when combined with immune checkpoint inhibitor drugs, can destroy primary tumors and trigger the immune system to attack distant metastases that the light never touched.²⁰ Other teams have engineered nanoparticles that use red light to trigger drug release and immune activation simultaneously.²¹ These are exciting developments in cancer treatment, but they are a completely different modality from the at-home or clinic-based red light panels and laser devices that people typically mean when they ask about red light therapy. If you see a headline claiming that red light “kills breast cancer cells,” check whether the study actually used a photosensitizer. If it did, the results do not tell you anything about PBM safety.

What Clinical Guidelines Say

As of now, PBM has formal clinical guideline support for exactly one cancer-related application: preventing and managing oral mucositis in patients undergoing certain types of cancer treatment, including stem cell transplants and head-and-neck radiation with or without chemotherapy.²² These guidelines come from the Multinational Association of Supportive Care in Cancer, which reviewed the evidence and recommended specific protocols with defined wavelengths and doses. For breast cancer specifically, no equivalent guideline exists. The radiodermatitis and lymphedema applications are still considered investigational, even though the radiodermatitis data are fairly strong.

This gap between promising clinical data and formal guideline endorsement is something to keep in mind. Most oncologists will not object to PBM being used for radiation skin care if the treating radiation oncologist is aware and agrees. But using red light therapy independently, without your treatment team’s knowledge, is a different situation. At minimum, your oncologist should know about any light-based treatments you are using, where the device is being applied, and at what dose.

Dose and Wavelength Are Not Interchangeable

One thing that gets lost in the consumer conversation about red light therapy is how much the parameters matter. The clinical trials discussed above used specific wavelengths (typically 630 to 670 nm for red, or around 830 nm for near-infrared), specific energy densities (commonly 3 to 5 joules per square centimeter), and specific treatment schedules. Consumer devices sold for skin rejuvenation or pain relief may or may not deliver similar parameters. The lab study that found infrared laser could increase breast cancer cell proliferation used a dose of 25 joules per square centimeter, which is substantially higher than what most clinical protocols call for.⁴ The animal study that found no tumor growth effect used 5 joules per square centimeter.⁵

This is not a situation where “more is better” or “any red light device will do.” The preclinical data suggest that the biological response follows a biphasic curve: too little light does nothing, the right amount stimulates healthy tissue repair, and too much may push cells in unwanted directions. If you are using a consumer red light panel on your face for skin care while undergoing breast cancer treatment, that is a very different scenario from pressing a high-powered laser device against your chest wall. Location, dose, and wavelength all change the risk calculus.

When Red Light Therapy Should Be Avoided

Even researchers who are optimistic about PBM’s role in supportive cancer care tend to agree on a few boundaries. Direct application of red or infrared light over a known, active tumor site is not recommended outside of a clinical trial, because the theoretical risk of stimulating residual cancer cells has not been ruled out. The angiogenesis data and the cell proliferation findings at higher doses are enough to warrant that precaution. Similarly, if you are taking a photosensitizing medication for any reason, adding red light exposure could trigger unintended photodynamic effects in tissue you did not mean to target.

The timing of treatment also matters. Using PBM to protect skin during active radiation therapy has clinical trial support and is a reasonable conversation to have with your radiation oncologist. Using red light therapy on your own months after treatment is finished, for general wellness or lingering side effects, is a grayer area where the risk is almost certainly lower but the evidence of benefit is also thinner. Applying red light directly over a reconstruction site, implant, or tissue expander is another question that has barely been studied at all, and your surgeon would be the right person to ask.

The honest state of the science is that PBM appears safe when used under clinical supervision for specific treatment side effects in breast cancer patients, based on the trials conducted so far. But “appears safe in the studies we have” is not the same as “proven safe for every use case.” The preclinical literature contains enough conflicting signals to justify keeping your oncology team in the loop before adding any form of red light therapy to your care routine.